This post was originally published on this site
https://i-invdn-com.investing.com/news/LYNXMPED2T082_M.jpg
Vera Therapeutics Inc (NASDAQ:VERA) 62% LOWER; announced the Phase 2b ORIGIN clinical trial of atacicept in patients with immunoglobulin A nephropathy (IgAN) met its primary endpoint.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT) 26% LOWER; announced that the FDA has notified the Company that no action will be taken on the Company’s new drug application (NDA) for vonoprazan, a novel potassium-competitive acid blocker (PCAB), under review as a treatment for erosive esophagitis, on or prior to the current Prescription Drug User Fee Act (PDUFA) target action date of January 11, 2023.
Smart Global Holdings Inc (NASDAQ:SGH) 8% HIGHER; reported Q1 EPS of $0.79, $0.20 better than the analyst estimate of $0.59. Revenue for the quarter came in at $465 million versus the consensus estimate of $447.18 million. SMART Global Holdings, Inc. sees Q2 2023 EPS of $0.45-$0.75, versus the consensus of $0.49. SMART Global Holdings, Inc. sees Q2 2023 revenue of $410-460 million, versus the consensus of $432 million.
CarMax (NYSE:KMX) 3% HIGHER; CEO, William Nash, bought 8,220 shares on 12/30/22 at $60.98.
Icosavax Inc (NASDAQ:ICVX) 2% HIGHER; Oppenheimer initiates coverage on with an Outperform rating and a price target of $27.00.
Progress Software Corporation (NASDAQ:PRGS) 1% HIGHER; entered into a definitive agreement to acquire MarkLogic, a leader in managing complex data and metadata and a Vector Capital portfolio company.
Okta, Inc (NASDAQ:OKTA) 1% HIGHER; SMBC Nikko Securities initiates coverage with an Outperform rating and a price target of $90.00.